Reardon, D. A., De Groot, J. F., Colman, H., Jordan, J. T., Daras, M., Clarke, J. L., … Peters, K. B. (2016). Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM). In Journal of Clinical Oncology (Vol. 34, pp. 2010–2010). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.2010

Reardon, David A., John Frederick De Groot, Howard Colman, Justin T. Jordan, Mariza Daras, Jennifer Leigh Clarke, Phioanh Leia Nghiemphu, Sarah C. Gaffey, and Katherine B. Peters. “Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).” In Journal of Clinical Oncology, 34:2010–2010. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.2010.

Reardon DA, De Groot JF, Colman H, Jordan JT, Daras M, Clarke JL, et al. Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 2010–2010.

Reardon, David A., et al. “Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 2010–2010. Crossref, doi:10.1200/jco.2016.34.15_suppl.2010.

Reardon DA, De Groot JF, Colman H, Jordan JT, Daras M, Clarke JL, Nghiemphu PL, Gaffey SC, Peters KB. Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 2010–2010.